Aspirin-Sulfinpyrazone in Prophylaxis of Deep Venous Thrombosis in Total Hip Replacement

• Published in: JAMA : the journal of the American Medical Association Vol. 250; no. 19; pp. 2649 - 2654
• Main Authors: Sautter, Richard D, Koch, Edgar L, Myers, William O, Ray, Jefferson R, Mazza, Joseph J, Larson, David E, Chen, Hong-Mo, Milbauer, John P, Treuhaft, Paul S, Plotka, Edward D, Wenzel, Frederick J, Nycz, Gregory, Pierce, Willard E
• Format: Journal Article
• Language: English
• Published: Chicago, IL American Medical Association 18-11-1983
• Subjects: Adult; Aged; Aspirin - administration & dosage; Biological and medical sciences; Cardiovascular system; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Hip Prosthesis; Humans; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Postoperative Complications - prevention & control; Random Allocation; Sex Factors; Sulfinpyrazone - administration & dosage; Thrombophlebitis - prevention & control; Vascular wall; Human; Postoperative; Prevention; Vascular disease; Drug combination; Chemotherapy; Treatment; Deep vein thrombosis; Salicylates; Antiplatelet agent; Prothesis
• ISSN: 0098-7484; 1538-3598
• DOI: 10.1001/jama.1983.03340190051031

In postoperative hip arthroplasty patients, treatment with aspirin and sulfinpyrazone resulted in a statistically significant reduction of venographically diagnosed thrombi in the proximal veins of the leg. This reduction was most apparent in thrombi that involved the iliac vein. When compared with their placebo-treated counterparts, female patients who received the active treatment experienced a statistically significant 75% reduction of thrombosis, compared with a 32% reduction for men that was not statistically significant. There were no serious adverse effects. Factors were identified that may influence the result of drug prophylaxis trials in deep-vein thrombosis.(JAMA 1983;250:2649-2654)